OSSTEC announced updates supporting its U.S. market entry. The company’s first product, the ASCENT cementless unicompartmental knee supported by the CLARITY instrumentation system, is designed to improve biological fixation without cement, streamline surgical workflows, and enable reproducible adoption by surgeons.
Further, the company appointed Dr. Nick Pachuda to its Board of Directors and established U.S. operations led by U.S. Commercial Lead Christopher Campbell.
These developments, supported by the successful close of new funding, mark steps in OSSTEC’s strategy to establish a U.S. presence ahead of regulatory clearance and the commercial launch of ASCENT. The capital will primarily support the establishment and scaling of U.S. operations, commercial readiness, and surgeon training infrastructure, alongside continued regulatory and clinical progress.
The U.S. expansion focuses on:
Surgeon engagement and KOL network development
Hospital and clinical partner onboarding
Strategic partnering and business development initiatives
Preparation for U.S. regulatory clearance and commercial launch
Max Munford, PhD, Founder and CEO of OSSTEC, said, “We are building more than a product launch. We are building a U.S.-centred platform for surgeon engagement, strategic partnership, and scalable growth that will support ASCENT’s commercial success and future fundraising.”
OSSTEC announced updates supporting its U.S. market entry. The company's first product, the ASCENT cementless unicompartmental knee supported by the CLARITY instrumentation system, is designed to improve biological fixation without cement, streamline surgical workflows, and enable reproducible adoption by surgeons.
Further, the company...
OSSTEC announced updates supporting its U.S. market entry. The company’s first product, the ASCENT cementless unicompartmental knee supported by the CLARITY instrumentation system, is designed to improve biological fixation without cement, streamline surgical workflows, and enable reproducible adoption by surgeons.
Further, the company appointed Dr. Nick Pachuda to its Board of Directors and established U.S. operations led by U.S. Commercial Lead Christopher Campbell.
These developments, supported by the successful close of new funding, mark steps in OSSTEC’s strategy to establish a U.S. presence ahead of regulatory clearance and the commercial launch of ASCENT. The capital will primarily support the establishment and scaling of U.S. operations, commercial readiness, and surgeon training infrastructure, alongside continued regulatory and clinical progress.
The U.S. expansion focuses on:
Surgeon engagement and KOL network development
Hospital and clinical partner onboarding
Strategic partnering and business development initiatives
Preparation for U.S. regulatory clearance and commercial launch
Max Munford, PhD, Founder and CEO of OSSTEC, said, “We are building more than a product launch. We are building a U.S.-centred platform for surgeon engagement, strategic partnership, and scalable growth that will support ASCENT’s commercial success and future fundraising.”
Copy to clipboard 
